- Home
- TURN vs QNCX Comparison
TURN vs QNCX Comparison
Compare TURN & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- QNCX
- Stock Information
- Founded
- TURN 1981
- QNCX 2012
- Country
- TURN United States
- QNCX United States
- Employees
- TURN N/A
- QNCX N/A
- Industry
- TURN Finance/Investors Services
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TURN Finance
- QNCX Health Care
- Exchange
- TURN Nasdaq
- QNCX Nasdaq
- Market Cap
- TURN 39.9M
- QNCX 44.0M
- IPO Year
- TURN N/A
- QNCX 2019
- Fundamental
- Price
- TURN $4.06
- QNCX $0.95
- Analyst Decision
- TURN
- QNCX Strong Buy
- Analyst Count
- TURN 0
- QNCX 5
- Target Price
- TURN N/A
- QNCX $8.00
- AVG Volume (30 Days)
- TURN 31.5K
- QNCX 536.2K
- Earning Date
- TURN 05-27-2025
- QNCX 05-13-2025
- Dividend Yield
- TURN N/A
- QNCX N/A
- EPS Growth
- TURN N/A
- QNCX N/A
- EPS
- TURN N/A
- QNCX N/A
- Revenue
- TURN $194,813.00
- QNCX N/A
- Revenue This Year
- TURN N/A
- QNCX N/A
- Revenue Next Year
- TURN N/A
- QNCX N/A
- P/E Ratio
- TURN N/A
- QNCX N/A
- Revenue Growth
- TURN 254.25
- QNCX N/A
- 52 Week Low
- TURN $3.12
- QNCX $0.51
- 52 Week High
- TURN $4.23
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- TURN 60.66
- QNCX 32.57
- Support Level
- TURN $3.68
- QNCX $0.98
- Resistance Level
- TURN $4.19
- QNCX $1.06
- Average True Range (ATR)
- TURN 0.30
- QNCX 0.09
- MACD
- TURN 0.02
- QNCX -0.00
- Stochastic Oscillator
- TURN 72.58
- QNCX 7.08
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.